Blood test may guide safer chemo for hodgkin lymphoma patients

NCT ID NCT06745076

Recruiting now Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 5 times

Summary

This phase 2 trial is testing whether a blood test that measures tumor DNA (ctDNA) can help doctors safely reduce the amount of chemotherapy for people with advanced Hodgkin lymphoma. After two cycles of standard chemo, patients with undetectable ctDNA may receive fewer total cycles, while those with detectable ctDNA continue standard treatment. The goal is to maintain effectiveness while minimizing side effects from chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab, doxorubicin, vinblastine, dacarbazine
What this could lead to: If successful, this approach could allow many patients with advanced Hodgkin lymphoma to receive fewer chemotherapy cycles without compromising cancer control, reducing side effects.
What could go wrong: This is a phase 2 trial with only 125 participants, so results are preliminary. The ctDNA-guided reduction may not work for everyone, and some patients might still need full chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HODGKIN LYMPHOMA CLASSIC HODGKIN LYMPHOMA LUGANO CLASSIFICATION STAGE III HODGKIN LYMPHOMA AJCC V8 LUGANO CLASSIFICATION STAGE IV HODGKIN LYMPHOMA AJCC V8

Contacts and locations

Locations

City of Hope
RECRUITING

Irvine, California, 92618, United States
Dana-Farber Cancer Institute
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Stanford Cancer Institute Palo Alto
RECRUITING

Palo Alto, California, 94304, United States
Washington University in St. Louis
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.